Q-omics provides the consensus-scored NCOR2 profile across patient tissues and cancer cell-line models. NCOR2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, NCOR2 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, NCOR2 RNA expression shows 20,129 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight MESO, KIRC, and ACC as cancer lineages where NCOR2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NCOR2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NCOR2 survival associations across molecular data types. NCOR2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (9) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NCOR2 RNA expression–survival associations across cancer types. High NCOR2 expression shows unfavorable associations in MESO, CESC, LIHC, LUSC and OV, but favorable associations in UCS. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for NCOR2 RNA expression.
This table summarizes NCOR2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NCOR2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NCOR2 shows higher tumor expression in KIRC, HNSC, LIHC, COAD, STAD and KICH. The KIRC box plot shows higher NCOR2 RNA expression in tumor versus normal tissue (log2 FC = +1.140, t-test p < 0.001).
This table shows molecular features associated with NCOR2 in patient tissues and cancer cell lines. In patient samples, NCOR2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, NCOR2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and UPPER_AERODIGESTIVE_TRACT.
